PHDs and HIFs can be potentially targeted for the treatment of iron-related disorders such as anemia, chronic kidney disease (CKD), and polycythemia, whereas HIF2α is an essential target for polycythemia-related disorders [106]. The gene discussed is EPAS1; the disease is anemia (phenotype).